| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 6054980 | Oral Oncology | 2014 | 9 Pages | 
Abstract
												HRQoL declines after treatment but recovers to baseline levels, generally within 12 months. However, xerostomia-related HRQoL deficits may remain long-term. Combined chemoradiotherapy showed a trend toward worse HRQoL compared with RT alone. Intensity modulated radiotherapy (IMRT) yields better HRQoL compared with conventional or three-dimensional conformal radiotherapy. Baseline HRQoL may independently predict local-regional control and overall survival. Future research should incorporate HRQoL into phase III trials. However, adequate effort and journal space must be afforded to the HRQoL results of these studies to ensure proper reporting methods are followed, allowing clinicians to incorporate HRQoL into patient counseling and clinical decision making.
											Keywords
												
											Related Topics
												
													Health Sciences
													Medicine and Dentistry
													Dentistry, Oral Surgery and Medicine
												
											Authors
												Jonathan Klein, Jonathan Livergant, Jolie Ringash, 
											